Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar(United States Food and Drug Administration), Lijun Zhang(United States Food and Drug Administration), Michael Untch(Helios Hospital Berlin-Buch), Keyur Mehta(German Breast group), Joseph P. Costantino(NSABP Foundation), Norman Wolmark(NSABP Foundation), Hervé Bonnefoi(Institut Bergonié), David Cameron(University of Edinburgh), Luca Gianni(San Raffaele University of Rome), Pinuccia Valagussa(Fondazione Michelangelo), Sandra M. Swain(MedStar Washington Hospital Center), Tatiana M. Prowell(United States Food and Drug Administration), Sibylle Loibl(German Breast group), D. Lawrence Wickerham(NSABP Foundation), Jan Bogaerts(European Organisation for Research and Treatment of Cancer), José Baselga(Memorial Sloan Kettering Cancer Center), Charles M. Perou(UNC Lineberger Comprehensive Cancer Center), Gideon M. Blumenthal(United States Food and Drug Administration), Jens‐Uwe Blohmer(Sankt Gertrauden Krankenhaus), Eleftherios P. Mamounas(Orlando Health), Jonas Bergh(Karolinska Institutet), Semiglazov Vf(Institute of Oncology NN Petrov), Robert Justice(United States Food and Drug Administration), Holger Eidtmann, Soonmyung Paik(NSABP Foundation), Martine Piccart(Institut Jules Bordet), Rajeshwari Sridhara(United States Food and Drug Administration), Peter A. Fasching(Universitätsklinikum Erlangen), Leen Slaets(European Organisation for Research and Treatment of Cancer), Shenghui Tang(United States Food and Drug Administration), Bernd Gerber(Universitäts Frauenklinik), Charles E. Geyer(Virginia Commonwealth University), Richard Pazdur(United States Food and Drug Administration), Nina Ditsch(Ludwig-Maximilians-Universität München), Priya Rastogi(NSABP Foundation), W. Eiermann(Ludwig-Maximilians-Universität München), Gϋnter von Minckwitz(German Breast group)
Cited by 4,678Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis